Department of Internal Medicine, Seoul National University College of Medicine, Seoul, 03080, South Korea.
Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, South Korea.
BMC Med. 2022 May 4;20(1):181. doi: 10.1186/s12916-022-02383-4.
Practical guidance is needed regarding the vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals in resource-limited countries. It includes the number of vaccine doses that should be given to unvaccinated patients who experienced COVID-19 early in the pandemic.
We recruited COVID-19 convalescent individuals who received one or two doses of an mRNA vaccine within 6 or around 18 months after a diagnosis of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Their samples were assessed for IgG-binding or neutralizing activity and cell-mediated immune responses against SARS-CoV-2 wild-type and variants of concern.
A total of 43 COVID-19 convalescent individuals were analyzed in the present study. The results showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months. A second dose of vaccine did not significantly increase immune responses.
One dose of mRNA vaccine should be considered sufficient to elicit a broad immune response even around 18 months after a COVID-19 diagnosis.
在资源有限的国家，需要针对新冠肺炎（COVID-19）恢复期个体的疫苗接种提供实用指导。这包括应向在大流行早期感染严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）但未接种疫苗的患者接种多少剂疫苗。
我们招募了 COVID-19 恢复期个体，他们在 SARS-CoV-2 感染后 6 个月或大约 18 个月内接受了一剂或两剂 mRNA 疫苗。评估了他们的 IgG 结合或中和活性以及针对 SARS-CoV-2 野生型和关注变异株的细胞介导免疫反应。
本研究共分析了 43 名 COVID-19 恢复期个体。结果表明，在 6 个月内和大约 18 个月内接种疫苗的患者中，针对 SARS-CoV-2 野生型和关注变异株（包括奥密克戎变异株）的体液和细胞免疫反应相当。第二剂疫苗接种不会显著增加免疫反应。
即使在 COVID-19 诊断后大约 18 个月，一剂 mRNA 疫苗也应被认为足以引发广泛的免疫反应。
